OncoTherapy Science, Inc. (TYO:4564)

Japan flag Japan · Delayed Price · Currency is JPY
20.00
0.00 (0.00%)
At close: Feb 6, 2026
-20.00%
Market Cap7.53B +15.5%
Revenue (ttm)956.00M +99.6%
Net Income-825.00M
EPS-2.92
Shares Out376.64M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume34,508,300
Average Volume32,489,405
Open20.00
Previous Close20.00
Day's Range19.00 - 20.00
52-Week Range19.00 - 35.00
Beta0.21
RSI40.22
Earnings DateFeb 6, 2026

About OncoTherapy Science

OncoTherapy Science, Inc. engages in research and development of anti-body drugs; and the genome analysis of cancer, liquid biopsy, and development of new immunotherapy in Japan. Its development pipeline includes OTS167, a small molecular compound that targets the maternal embryonic leucine zipper kinase inhibitor that is in Phase I/II clinical trials for the treatment of acute myeloid leukemia, as well as in Phase I clinical trials for the treatment of breast cancer; and OTS964, a small molecule TOPK inhibitor currently under non-clinical stag... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2001
Employees 47
Stock Exchange Tokyo Stock Exchange
Ticker Symbol 4564
Full Company Profile

Financial Performance

In fiscal year 2025, OncoTherapy Science's revenue was 750.00 million, an increase of 22.95% compared to the previous year's 610.00 million. Losses were -815.00 million, -36.72% less than in 2024.

Financial Statements